HIF Inhibitors: Status of Current Clinical Development

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166

Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.

Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173

HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion

Du, R., Lu, K. V., Petritsch, C. K., Liu, P., Ganß, R., Passegue, E. A., Song, H., VandenBerg, S. R., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,166

Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1

Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154

Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene.

Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990

Hypoxia-Inducible Factor 1 (HIF-1) Pathway

Semenza, G. L. (2007) · Science s STKE · doi:10.1126/stke.4072007cm8 · Cited by 970

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma

Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Kelly, W. K., O’Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M. L., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Secrist, J. P., Schwartz, L. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 906

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687

Passing the baton: the HIF switch

Koh, M. Y., & Powis, G. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.06.004 · Cited by 589

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma

Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448

Gelatinase B: a tuner and amplifier of immune functions

Opdenakker, G., den Steen, P. E. V., & Damme, J. V. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02023-3 · Cited by 398

Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

Krieg, M., Haas, R., Brauch, H., Acker, T., Flamme, I., & Plate, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203938 · Cited by 396

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A. P., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 360

Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.

Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Ki, K., Hosokawa, M., & Asaka, M. (2001) · PubMed · Cited by 340

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336

Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival

Choudhry, H., Albukhari, A., Morotti, M., Haider, S. A., Moralli, D., Smythies, J., Schödel, J., Green, C., Camps, C., Buffa, F. M., et al. (2014) · Oncogene · doi:10.1038/onc.2014.378 · Cited by 323

Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia

Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0425 · Cited by 300

Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2672 · Cited by 264

Intratumoral hypoxia, radiation resistance, and HIF-1

Semenza, G. L. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00118-7 · Cited by 238

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Krug, L. M., Kindler, H. L., Calvert, H., Manegold, C., Tsao, A. S., Fennell, D. A., Öhman, R., Plummer, R., Eberhardt, W., Fukuoka, K., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70056-2 · Cited by 215

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 201

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Heath, E. I., Hillman, D. W., Vaishampayan, U. N., Sheng, S., Sarkar, F. H., Harper, F. W. K., Gaskins, M., Pitot, H. C., Tan, W. W., Ivy, S. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0221 · Cited by 186

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179

Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel–Lindau gene mutation status

Messai, Y., Gad, S., Noman, M. Z., Le Teuff, G., Couve, S., Janji, B., Kammerer, S. F., Rioux-Leclerc, N., Hasmim, M., Ferlicot, S., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.029 · Cited by 168

Nelfinavir Down-regulates Hypoxia-Inducible Factor 1α and VEGF Expression and Increases Tumor Oxygenation: Implications for Radiotherapy

Pore, N., Gupta, A., Cerniglia, G. J., Jiang, Z., Bernhard, E. J., Evans, S. M., Koch, C. J., Hahn, S. M., & Maity, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1239 · Cited by 154

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

Ronnen, E. A., Kondagunta, G. V., Ishill, N. M., Sweeney, S. M., DeLuca, J., Schwartz, L. H., Bacik, J., & Motzer, R. J. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9208-z · Cited by 147

Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells

Zhao, D., Zhai, B., He, C., Tan, G., Jiang, X. L., Pan, S., Dong, X., Wei, Z., Ma, L., Qiao, H., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.026 · Cited by 146

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma

Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma

Ogura, M., Ando, K., Suzuki, T., Ishizawa, K., Oh, S. Y., Itoh, K., Yamamoto, K., Au, W. Y., Tien, H., Matsuno, Y., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12819 · Cited by 114

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Harrison, M. R., Hahn, N. M., Пили, Р., Oh, W. K., Hammers, H. J., Sweeney, C. J., Kim, K., Perlman, S. B., Arnott, J., Sidor, C. F., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9455-x · Cited by 110

Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial

Matei, D. E., Schilder, J. M., Sutton, G. P., Perkins, S. M., Breen, T., Quon, C. Y., & Sidor, C. F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.05.042 · Cited by 101

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors

Kulke, M. H., Chan, J. A., Meyerhardt, J. A., Zhu, A. X., Abrams, T. A., Blaszkowsky, L. S., Regan, E. M., Sidor, C. F., & Fuchs, C. S. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1478-7 · Cited by 88

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J. C., Пили, Р., Logan, T. F., Carducci, M. A., Arnott, J., Treston, A. M., Wilding, G., & Liu, G. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9618-9 · Cited by 88

Hypoxia‐inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression

Sowa, T., Menju, T., Chen-Yoshikawa, T. F., Takahashi, K., Nishikawa, S., Nakanishi, T., Shikuma, K., Motoyama, H., Hijiya, K., Aoyama, A., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.991 · Cited by 88

A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1α, 2α and 3α)

Luo, J. C., & Shibuya, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204228 · Cited by 80

Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway

Wu, H., Huang, S., Chen, Z., Liu, W., Zhou, X., & Zhang, D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4255 · Cited by 77

Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma

Rajkumar, S. V., Richardson, P. G. G., Lacy, M. Q., Dispenzieri, A. A., Greipp, P. R., Witzig, T. E., Schlossman, R. L., Sidor, C. F., Anderson, K. C., & Gertz, M. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0807 · Cited by 76

HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer

Yang, J., Zhang, X., Zhang, Y., Zhu, D., Zhang, L., Li, Y., Zhu, Y., Li, D., & Zhou, J. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0298-y · Cited by 76

Phase II trial of vorinostat in advanced melanoma

Haas, N. B., Quirt, I. C., Hotte, S. J., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0066-9 · Cited by 71

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma

Dai, X., Pi, G., Yang, S., Chen, G. Y., Liu, L., & Dong, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.02.014 · Cited by 63

Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

Garrett, C. R., Bekaii‐Saab, T. S., Ryan, T., Fisher, G. A., Clive, S., Kavan, P., Shacham‐Shmueli, E., Buchbinder, A., & Goldberg, R. M. (2013) · Cancer · doi:10.1002/cncr.28358 · Cited by 62

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

O’Keefe, S. J., Hoffman-Censits, J. H., Cohen, R. B., Mamtani, R., Heitjan, D. F., Eliasof, S. D., Nixon, A. B., Turnbull, B., Garmey, E. G., Gunnarsson, Ö., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw188 · Cited by 55

Prognosis value of HIF-1α expression in patients with non-small cell lung cancer

Wang, Q., Hu, D.-F., Rui, Y., Jiang, A., Liu, Z., & Huang, L. (2014) · Gene · doi:10.1016/j.gene.2014.03.025 · Cited by 52

HIF-1α Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function

Yoo, Y., Christensen, J., & Huang, E. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2360 · Cited by 50

Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis

Fan, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1746 · Cited by 49

HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer

Sun, Y., Guan, Z., Liang, L., Cheng, Y., Zhou, J., Li, J., & XU, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.4536 · Cited by 41

HIF-2α not HIF-1α overexpression confers poor prognosis in non–small cell lung cancer

Gao, Z., Wang, Y., Yuan, W.-D., Yuan, J.-Q., & Yuan, K. (2017) · Tumor Biology · doi:10.1177/1010428317709637 · Cited by 38

HIF-1α Promotes Breast Cancer Cell MCF-7 Proliferation and Invasion Through Regulating miR-210

Zhang, Y., Yan, J., Wang, L., Dai, H., Li, N., Hu, W., & Cai, H. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2270 · Cited by 37

HIF-1α- and hypoxia-dependent immune responses in human CD4+CD25high T cells and T helper 17 cells

Bollinger, T., Gies, S. E., Naujoks, J., Feldhoff, L., Bollinger, A., Solbach, W., & Rupp, J. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a0813-426rr · Cited by 33

Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis

ZHENG, Y., Ni, Y., Huang, X., Wang, Z., & Han, W. (2013) · Oncology Letters · doi:10.3892/ol.2013.1185 · Cited by 32

Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis

Lodewijk, L., van Diest, P. J., van der Groep, P., ter Hoeve, N. D., Schepers, A., Morreau, J., Bonenkamp, J. J., Grunsven, A. C. H. V. E., Kruijff, S., van Hemel, B. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15622 · Cited by 30

SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1α

OKUNO, T., Kawai, K., Hata, K., Murono, K., Emoto, S., Kaneko, M., Sasaki, K., Nishikawa, T., Tanaka, T., & Nozawa, H. (2018) · Anticancer Research · doi:10.21873/anticanres.12598 · Cited by 30

HIF-1–Dependent Stromal Adaptation to Ischemia Mediates In Vivo Tumor Radiation Resistance

Schwartz, D. L., Bankson, J. A., Bidaut, L. M., He, Y., Williams, R. R., Lemos, R., Thitai, A. K., Oh, J., Volgin, A., Soghomonyan, S., et al. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0469 · Cited by 27

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

Oki, Y., Copeland, A. R. M., Romaguera, J. E., Fayad, L., Fanale, M. A., Faria, S. D. C., Medeiros, L. J., Ivy, P. S., & Younes, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.631236 · Cited by 21

HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma

Lai, X., Liu, S., Tsai, Y.-T., Sun, G., Chang, S., Huang, S., & Cha, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17923 · Cited by 19

The prognosis outcome of oral squamous cell carcinoma using HIF-2α

Lim, E., Kuo, C., Tu, H., & Yang, C. (2017) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2017.06.005 · Cited by 19

Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin

Gao, Z., Yuan, W.-D., Yuan, J.-Q., Yuan, K., & Wang, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.906107 · Cited by 12

Relationship between CD4+CD25+ Treg and expression of HIF-1α and Ki-67 in NSCLC patients.

He, L.-Y., Li, L., Guo, M.-L., Zhang, Y., & Hz, Z. (2015) · PubMed · Cited by 10

Hypoxia and the Tumor Microenvironment

Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 397

Hypoxia-Driven Immune Escape in the Tumor Microenvironment

Vito, A., El-Sayes, N., & Mossman, K. L. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 287

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential

Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 270

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

Ghosh, P., Vidal, C., Dey, S., & Li, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 272

Targeting hypoxia-inducible factors: therapeutic opportunities and challenges

Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514

Hypoxia-inducible factors: arbitrators of cancer progression, inhibitors, and therapy

Dutta, P., Sheikh, A. A., Dan, S., & Upadhyay, S. K. (2024) · De Gruyter eBooks · doi:10.1515/9783111349541-008

Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics

Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Yu, T., Tang, B., & Sun, X. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.489 · Cited by 202

Targeting the hypoxia-inducible factor (HIF) pathway in cancer

Poon, E., Harris, A. L., & Ashcroft, M. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001173 · Cited by 215